Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
29th Nov 2005, 01:13 GMT
Somatic activating mutations in EGFR identify a subset of non-small cell lung cancer that respond to tyrosine kinase inhibitors. Acquisition of drug resistance is linked to a specific secondary somatic mutation, EGFR T790M. Here we describe a family with multiple cases of non-small cell lung cancer associated with germline transmission of this mutation. Four of six tumors analyzed showed a secondary somatic activating EGFR mutation, arising in cis with the germline EGFR mutation T790M. These observations implicate altered EGFR signaling in genetic susceptibility to lung cancer.
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR related news:
- Q&A with a Lung Cancer Survivor — Science Blog -
- Novartis Issues Breast Cancer Drug Warning (Associated Press) —
- Novartis Warns Doctors of Misusing Cancer Drug — RedOrbit News - Health
- Cancer Drug No Fertility Treatment — Health News: CBSnews.com
- Novartis issues breast cancer drug warning. — Environmental Health News
- Novartis Warns About Breast Cancer Drug Use — NYNewsday.com Health and Science headlines
- $8.5 million to fund cancer drug development — Professional organisations latest news on Laboratorytalk
- Novartis Issues Breast Cancer Drug Warning (AP) — Yahoo! News: Top Stories
- Novartis Issues Breast Cancer Drug Warning — AP Top Headlines At 8:24 p.m. EST
- Warning issued for breast cancer drug — MSNBC.com: Health